TBI is an urgent and prominent public health challenge, impacting millions each year as a result of head trauma from accidents, falls, sports-related incid...
SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central...
QIAGEN announced the expansion of its sample technologies portfolio with the introduction of two new products aimed at supporting researchers in managing d...
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an eq...
Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease bioma...
Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces a collaboration with Uli...
Olympus assessed the issue after receiving complaints of adverse events involving serious patient injury, where patients may suffer burns to the airway or ...
Both of these biomarkers are included in the company’s commercially available Precivity™ blood tests, which help healthcare providers determine...
Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibi...
At the American Society of Nephrology’s (ASN) Kidney Week 2023, Bayer today announced pharmacodynamic data on Kerendia® (finerenone), the first n...
Revenue of $671 million; (6)% reported growth; (7)% organic growth; 1% non-COVID organic growth GAAP EPS of $0.08; Adjusted EPS from continuing oper...
Collaboration to develop, manufacture and commercialize next-generation selective PARP1 inhibitor HRS-1167, with option to develop, manufacture and comme...
Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mut...
American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study r...
© 2025 Biopharma Boardroom. All Rights Reserved.
